Enoxaparin sodium

Generic Name: Enoxaparin sodium

Brand Names: Lovenox, Inhixa

Drug Type: Small Molecule

CAS Number: 9005-49-6

Unique Ingredient Identifier: E47C0NF7LV

Background: Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated heparin, without increasing the risk of serious bleeding.

Indication: Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.

Enoxaparin is also indicated in the prophylaxis of DVT in abdominal surgery, hip replacement, knee replacement, or medical patients with severely restricted mobility during acute illness. Additionally, enoxaparin is indicated for the inpatient treatment of DVT with or without pulmonary embolism and the treatment of outpatient DVT without pulmonary embolism.

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina

Associated Therapies: Percutaneous Coronary Intervention (PCI)

Clinical Trials

Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: a Pilot Project

Phase 2

Recruiting

Conditions: Adverse Pregnancy Outcome

Interventions: Drug: Lovenox 40mg

First Posted Date: 2023-08-22

Last Posted Date: 2024-11-14

Lead Sponsor: NorthShore University HealthSystem

Target Recruit Count: 20

Registration Number: NCT06004674

Locations: 🇺🇸
NorthShore University HealthSystem, Evanston, Illinois, United States

A Novel COMBinATorial Therapy with Albumin and Enoxaparin in Patients with Decompensated Cirrhosis At High-risk of Poor Outcome (COMBAT Trial).

Phase 2

Recruiting

Conditions: Liver Cirrhosis
Decompensated Cirrhosis of Liver
Acute on Chronic Liver Failure (ACLF)

Interventions: Drug: Human albumin
Drug: Enoxaparin
Drug: Standard medical treatment

First Posted Date: 2023-06-08

Last Posted Date: 2025-03-19

Lead Sponsor: European Foundation for Study of Chronic Liver Failure

Target Recruit Count: 90

Registration Number: NCT05895136

Locations: 🇬🇧
Royal Free Hospital, London, United Kingdom
🇫🇷
Hôpital Beaujon, Clichy, France
🇩🇪
Universitätsklinikum Aachen AöR, Aachen, Germany

and more 6 locations

Postpartum Heparin Against Venous Thromboembolism: a Pilot Randomized Controlled Trial

Phase 3

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: Enoxaparin

First Posted Date: 2023-05-26

Last Posted Date: 2023-05-26

Lead Sponsor: University Hospital, Geneva

Target Recruit Count: 77

Registration Number: NCT05878899

Locations: 🇨🇭
Geneva University Hospitals, Geneve, Switzerland

SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Phase 2

Completed

Conditions: Prevention of Venous Thromboembolism After Knee Arthroplasty

Interventions: Drug: Enoxaparin sodium injection
Drug: SHR-2004 injection

First Posted Date: 2023-03-02

Last Posted Date: 2025-01-20

Lead Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd

Target Recruit Count: 353

Registration Number: NCT05752461

Locations: 🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China

THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)

Phase 4

Recruiting

Conditions: Venous Thromboembolism
Varicose Veins

Interventions: Drug: Dalteparin Sodium
Drug: Tinzaparin Sodium
Drug: Enoxaparin Sodium
Drug: Rivaroxaban
Drug: Apixaban
Drug: Dabigatran Etexilate

First Posted Date: 2023-02-21

Last Posted Date: 2025-05-02

Lead Sponsor: Imperial College London

Target Recruit Count: 6660

Registration Number: NCT05735639

Locations: 🇬🇧
Imperial College Hospital NHS Foundation Trust, London, United Kingdom

A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants

Phase 2

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: Apixiban
Drug: REGN9933
Drug: Enoxaparin

First Posted Date: 2022-11-16

Last Posted Date: 2024-06-06

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 373

Registration Number: NCT05618808

Locations: 🇧🇬
MBAL Heart and Brain Hospital, Pleven, Bulgaria
🇧🇪
Ziekenhuis Oost-Limburg- Campus Sint-Jan, Genk, Limburg, Belgium
🇭🇺
Department of Orthopedics, Somogy County Mór Kaposi Teaching Hospital, Kaposvar, Hungary

and more 13 locations